Liquidia Corporation

10/02/2024 | Press release | Distributed by Public on 10/02/2024 04:16

Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.